33 independently checked trend briefs about this subject, newest first.
headlinez.news detected 33 source-qualified news clusters connected to Pharmaceuticals between June 23, 2026 and July 30, 2026. They span 2 newsroom categories and average 7.9 independent sources per brief.
This hub includes only briefs supported by at least four sources and passed by the site's verification gate. Raw or weak detections may exist but are excluded here. Topic matching is based on the entities and themes recorded with each brief; open a card to inspect its source links, publication time, verification label and velocity history. Read the methodology and editorial policy for the full rules.
Sanofi’s new CEO Garijo outlines an R&D restructuring and expansion plan as the company balances strong second-quarter earnings against investor concerns.
Medical professionals are reevaluating obesity treatment protocols as GLP-1 usage rises and questions emerge regarding long-term dependency and patient age limits.
Researchers are investigating whether common weight loss and nasal congestion medications may hold the key to slowing biological aging processes.
Otsuka’s newly approved ADHD drug Simtriyo opens a $615 million market and signals the company’s next big CNS push.
A new FDA‑approved drug gives ADHD patients of all ages a first‑in‑class treatment option.
GSK launches a $2.5 billion, three‑year savings drive to speed late‑stage trials and shift its research hub to Arizona.
Eli Lilly shares rise as new trial data shows the weight-loss drug retatrutide led to an average weight loss of 56 pounds.
Sanofi has officially discontinued development of its eczema drug amlitelimab, marking a significant shift in its pipeline strategy.
Merck is establishing voluntary licensing agreements and expanded access programs to prepare for the potential launch of a monthly oral HIV prevention pill.
Eli Lilly plans regulatory filings for its weight-loss drug retatrutide following successful Phase 3 trial results.
Proposed 100% tariffs on generic drugs have prompted market volatility and scrutiny regarding the future of the U.S. pharmaceutical supply chain.
Public discourse around GLP-1 medications is shifting as reports highlight broader health benefits, safety concerns, and the psychological impact of obesity.
Novo Nordisk has launched legal action against Eli Lilly, alleging that its rival engaged in deceptive marketing practices regarding weight-loss medications.
New tariff policy targets generic drug imports with a two-year implementation delay to encourage domestic manufacturing.
Federal hearings on marijuana rescheduling have concluded, sparking intense debate among industry stakeholders, pharmaceutical firms, and advocacy groups.
The FDA has granted approval for Lipfendra, the first oral PCSK9 cholesterol-lowering treatment developed by Merck.
A new generation of Alzheimer’s treatment is gaining attention as reports suggest potential to slow or stop the disease before symptoms emerge.
Biogen’s experimental tau-targeting drug, diranersen, has triggered market volatility following the release of mixed clinical trial data.
Johnson & Johnson shares dipped despite an earnings beat and raised guidance as investors weigh strong medicine sales against medical technology underperformance.
The FDA has resumed the public release of drug rejection letters, issuing 14 new Complete Response Letters following a three-month operational pause.
Coverage explores shifting trends in health insurance coverage and alternative access models for GLP-1 weight-loss medications.
Biogen’s tau-targeting Alzheimer’s drug shows early promise in slowing cognitive decline, sparking fresh debate in dementia research
Two widely available drugs show *limited* promise for long-COVID fatigue—raising cautious hope for millions.
Data confirms a record surge in GLP-1 weight-loss medication usage, with 11% of Americans currently reporting use of drugs like Wegovy.
The FDA has granted accelerated approval to Vera Therapeutics for its new kidney disease drug, Trutakna, targeting primary IgA Nephropathy.
AstraZeneca and Ionis face market volatility following the failure of their heart disease drug, Wainua, in a critical clinical trial.
An AI lab is now designing drugs—directly challenging Big Pharma’s profit-driven priorities.
Alibaba and a U.S. payment processor have reached a $600 million settlement with the Department of Justice regarding the sale of illegal goods.
The FDA has launched its PreCheck pilot program, selecting seven participants to accelerate domestic drug manufacturing capabilities.
The FDA has selected Eli Lilly and Regeneron for a pilot program designed to accelerate the review process for new pharmaceutical manufacturing facilities.
European regulators have recommended revoking marketing authorization for the Amgen drug Tavneos due to concerns regarding the reliability of study data.
Public scrutiny intensifies over the identity of an anonymous 79-year-old patient granted compassionate access to Eli Lilly’s experimental obesity drug, retatrutide.
Insurance coverage for GLP-1 weight loss medications faces significant volatility as employers and state programs reassess benefit packages.